COVID-19 in Patients Receiving CD20-depleting Immunochemotherapy for B-cell Lymphoma

COVID-19 in Patients Receiving CD20-depleting Immunochemotherapy for B-cell Lymphoma

The clinical and immunological impact of B-cell depletion in the context of coronavirus disease 2019 (COVID-19) is unclear. We conducted a prospectively planned analysis of COVID-19 in patients who received B-cell depleting anti-CD20 antibodies and chemotherapy for B-cell lymphomas. The control coho...

Full description

Bibliographic Details
Main Authors: Erik Gaitzsch, Verena Passerini, Elham Khatamzas, Carolin D. Strobl, Maximilian Muenchhoff, Clemens Scherer, Andreas Osterman, Michael Heide, Anna Reischer, Marion Subklewe, Alexandra Leutbecher, Benjamin Tast, Adrian Ruhle, Tobias Weiglein, Stephanie-Susanne Stecher, Hans J. Stemmler, Martin Dreyling, Philipp Girl, Enrico Georgi, Roman Wölfel, Laura Mateyka, Elvira D’Ippolito, Kilian Schober, Dirk H. Busch, Juliane Kager, Christoph D. Spinner, Matthias Treiber, Sebastian Rasch, Tobias Lahmer, Roman Iakoubov, Jochen Schneider, Ulrike Protzer, Christof Winter, Jürgen Ruland, Michael Quante, Oliver T. Keppler, Michael von Bergwelt-Baildon, Johannes Hellmuth, Oliver Weigert
Format: Article
Language:English
Published: Wiley 2021-07-01
Series:HemaSphere
Online Access:http://journals.lww.com/10.1097/HS9.0000000000000603

Internet

http://journals.lww.com/10.1097/HS9.0000000000000603

Similar Items